AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 11 min read$CRNX

Struthers Richard Scott sold (to issuer) $36.1M of CRNX

Struthers Richard Scott (President & CEO) sold (to issuer) 424,706 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($36.10M total) across 2 trades on 2026-09-01.

Original reporting
SEC EDGAR · Struthers Richard Scott
Published Sep 1, 2026, 8:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CRNX
Bearish
high confidence
Mentioned
$CRNX
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRNXBearishMed
01

Why it matters

The complete exit of the CEO's holdings could be interpreted as a bearish signal, prompting short interest.

02

Market read

Significant insider sell may affect CRNX price and sentiment in the biotech space.

03

What to watch

Potential tax planning or personal liquidity needs could drive the sale.

Relevance 7/10Novelty 8/10Timing: post-market 2026-09-01

Background

SEC Form 4 filing discloses insider transactions. This is the first public report of the sale.

Company-level read

Ticker impact

$CRNXBearishHigh confidence
Context

President & CEO Richard Scott sold all 424,706 shares for $36.1M, reducing his stake to zero.

Expected impact

downward pressure in the short term

Evidence & confidence

The sale represents a significant cash outflow by the CEO, often interpreted as a negative signal by investors.

Market effects

Sector

May raise concerns for the biotech sector about executive confidence.

Regional

Limited to U.S. biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    Crinetics Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ.

  • Executive
    Richard Scott

    President & CEO of Crinetics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRNX insider trading history →

Related articles

SEP 2
$VRTXHighAI 9/10

Vertex Completes $10 Billion Acquisition Of Crinetics Pharmaceuticals

Vertex Pharmaceuticals completed its $10 billion acquisition of Crinetics Pharmaceuticals, adding PALSONIFY and atumelnant to its portfolio. The deal, closed on September 1, 2026, is expected to boost revenue growth and become accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes, including a new CFO.

pulse2.com2 min
SEP 2
$CRNXLowAI 9/10

What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

simplywall.st2 min
SEP 1
$VRTXHighAI 9/10

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics Pharmaceuticals (CRNX) on September 1, 2026. The deal adds PALSONIFY and atumelnant to Vertex's pipeline, with potential peak revenue of $5B. Vertex also announced leadership changes, including Jonathan Poole's appointment as EVP, CFO in 2027 and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer.

investingnews.com2 min